Orthofix Files 8-K on Operations, Financials, Officer Compensation

TL;DR

**Orthofix filed a standard 8-K covering operations and compensation, nothing major.**

AI Summary

Orthofix Medical Inc. filed an 8-K on January 8, 2024, reporting on its results of operations, financial condition, and changes in officers' compensatory arrangements. This filing indicates standard operational updates and compliance with SEC regulations, rather than a specific major event like an acquisition or executive departure. For investors, this matters because it signals routine business operations and financial disclosures, which can be a neutral indicator unless specific details within the full filing reveal unexpected financial performance or significant compensation changes.

Why It Matters

This filing provides routine updates on Orthofix's financial health and executive compensation, which are essential for investors to monitor the company's ongoing performance and governance.

Risk Assessment

Risk Level: low — This 8-K appears to be a routine filing without immediate indications of significant positive or negative events, thus posing a low direct risk.

Analyst Insight

A smart investor would review the full 8-K document for specific details on financial performance and any changes to executive compensation or departures, as this summary only indicates the categories of information reported.

Key Numbers

• $0.10 — par value per share (par value of Orthofix's common stock)
• 214-937-2000 — business phone number (Orthofix Medical Inc.'s main contact number)

Key Players & Entities

• Orthofix Medical Inc. (company) — the registrant filing the 8-K
• Nasdaq Global Select Market (company) — the exchange where Orthofix's common stock is registered
• 0-19961 (dollar_amount) — Commission File Number
• 98-1340767 (dollar_amount) — IRS Employer Identification No.
• January 08, 2024 (date) — Date of earliest event reported

FAQ

Key Financial Figures

• $0.10 — nge on which registered Common stock, $0.10 par value per share OFIX Nasdaq Glo
• $12,500 — ng such date of termination), and (iii) $12,500 to be used for outplacement services. I
• $3,500,000 — awards with a grant date fair value of $3,500,000, and (ii) 2024 annual equity incentive
• $4,000,000 — awards with a grant date fair value of $4,000,000 (collectively, the “CEO Induceme
• $475,000 — s will receive an annual base salary of $475,000 per year, and a target bonus opportunit
• $1,800,000 — awards with a grant date fair value of $1,800,000 (collectively, the “CFO Induceme
• $225,000 — e level after-tax relocation payment of $225,000 to support establishing residency in th
• $500 — r up to twelve months, and will be paid $500 per hour for any consulting services pr
• $21,000 — o reimburse Mr. Kenny for approximately $21,000 in apartment lease costs in the Dallas,

Filing Documents

• ofix-20240108.htm (8-K) — 60KB
• ofix-ex10_1.htm (EX-10.1) — 192KB
• ofix-ex10_2.htm (EX-10.2) — 35KB
• ofix-ex99_1.htm (EX-99.1) — 177KB
• img50190239_0.jpg (GRAPHIC) — 2KB
• img236010591_0.jpg (GRAPHIC) — 3KB
• 0000950170-24-003420.txt ( ) — 637KB
• ofix-20240108.xsd (EX-101.SCH) — 23KB
• ofix-20240108_htm.xml (XML) — 4KB

02. Results of Operations and Financial Condition

Item 2.02. Results of Operations and Financial Condition. On January 9, 2024, Orthofix Medical Inc. (the “Company”) issued a news release announcing, among other things, its preliminary unaudited net sales for the fiscal quarter and year ended December 31, 2023. A copy of the press release is furnished herewith as Exhibit 99.1 and attached hereto. The information furnished in this Item 2.02, including the exhibit furnished herewith as Exhibit 99.1, will not be treated as “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section. This information will not be deemed incorporated by reference into any filing under the Securities Act of 1933, as amended (the “Securities Act”), or into another filing under the Exchange Act, unless that filing expressly incorporates by reference this Item 2.02 of this report.

02 Departure of Directors of Principal Officers; Election of Directors; Appointment of Principal Officers

Item 5.02 Departure of Directors of Principal Officers; Election of Directors; Appointment of Principal Officers. Appointment of Massimo Calafiore as President and Chief Executive Officer, and as Director; Appointment of Julie Andrews as incoming Chief Financial Officer On January 8, 2024, the Company’s Board of Directors (the “Board”) appointed Massimo Calafiore as the Company’s President and Chief Executive Officer, and Mr. Calafiore began service on such date. In addition, the Board expanded the size of the Board as of January 8, 2024 from eleven to twelve directors, and appointed Mr. Calafiore to fill the newly created seat. On the same date, the Board appointed Julie Andrews as the Company’s Chief Financial Officer, effective as of January 15, 2024, when Ms. Andrews is expected to begin employment with the Company. Mr. Calafiore, 52, served as the President and Chief Executive Officer of LimaCorporate S.p.A., a global orthopedic company focused on restoring motion through digital innovation and customized hardware, from September 2022 to January 2024, when it was acquired by Enovis Corporation. Previously, Mr. Calafiore served from September 2021 through August 2022 as Executive Vice President and Chief Commercial Officer of NuVasive, Inc., where he oversaw product marketing, commercial and commercial enablement functions, as well as NuVasive’s specialized orthopedics and clinical services. From October 2020 through August 2021, he served as NuVasive’s Executive Vice President, Global Business Units, where he was responsible for NuVasive’s product and services organization, including Spine, NuVasive Specialized Orthopedics (NSO) and NuVasive Clinical Services, and commercial enablement such as clinical professional development and global marketing. From 2017 until October 2020 he held various other leadership roles at NuVasive with increasing levels of responsibility, serving as Senior Vice Preside

01. Financial Statements and Exhibits

Item 9.01. Financial Statements and Exhibits. (d) Exhibits 10.1 Change in Control and Severance Agreement, dated as of January 8, 2024, between Orthofix Medical Inc. and Massimo Calafiore 10.2 Letter agreement, dated as of January 4, 2024, between Orthofix Medical Inc. and Julie Andrews 99.1 News release, dated January 9, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Orthofix Medical Inc. By: /s/ Geoffrey Gillespie Geoffrey Gillespie Interim Chief Financial Officer Date: January 9, 2024

View Full Filing

View this 8-K filing on SEC EDGAR